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Abstract
Background: Common mental disorders (CMD) such as anxiety and depression during the maternal period can
cause significant morbidity to the mother in addition to disrupting biological, attachment and parenting processes
that affect child development. Pharmacological treatment is a first-line option for moderate to severe episodes.
Many women prescribed pharmacological treatments cease them during pregnancy but it is unclear to what extent
non-pharmacological options are offered as replacement. There are also concerns that treatments offered may not
be proportionate to need in minority ethnic groups, but few data exist on treatment disparities in the maternal
period. We examined these questions in a multi-ethnic cohort of women with CMD living in Bradford, England
before, during and up to one year after pregnancy.
Methods: We searched the primary care records of women enrolled in the Born in Bradford cohort for diagnoses,
symptoms, signs (‘identification’), referrals for treatment, non-pharmacological and pharmacological treatment and
monitoring (‘treatment’) related to CMD. Records were linked with maternity data to classify women identified with
a CMD as treated prior to, and one year after, delivery. We examined rates and types of treatment during pregnancy,
and analysed potential ethnic group differences using adjusted Poisson and multinomial logistic regression models.
Results: We analysed data on 2,234 women with indicators of CMD. Most women were discontinued from
pharmacological treatment early in pregnancy, but this was accompanied by recorded access to non-drug
treatments in only 15 % at the time of delivery. Fewer minority ethnic women accessed treatments compared to
White British women despite minority ethnic women being 55–70 % more likely than White British women to
have been identified with anxiety in their medical record.
Conclusions: Very few women who discontinued pharmacological treatment early in their pregnancy were
offered other non-pharmacological treatments as replacement, and most appeared to complete their pregnancy
untreated. Further investigation is warranted to replicate the finding that minority ethnic women are more likely
to be identified as being anxious or having anxiety and understand what causes the variation in access to
treatments.
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Background
Common mental disorders (CMD) such as depression
and anxiety are chronic, relapsing conditions causing
significant morbidity with around one in four adults
being affected in one year [1]. While pregnancy and the
postnatal years may not be periods of increased preva-
lence they are sensitive periods, when these disorders
can disrupt biological, attachment and parenting pro-
cesses that subsequently affect child development and
behaviour [2, 3].
In general populations, pharmacotherapy and psycho-
logical therapies offer effective treatment for CMD, with
offer and uptake of specific modalities, or multi-modal
treatment, informed by disorder type, current episode
severity, past history and patient preference. Treatment
with pharmaceuticals is highly prevalent; studies of gen-
eral (not pregnancy specific) primary-care populations
indicating that 63 % of UK patients treated for anxiety and
98 % treated for incident depression receive prescriptions,
and in Germany insurance data indicates pharmacother-
apy outweighs psychological therapy for patients with
major depression by more than 4:1 [4–6]. Pharmacological
treatment duration may be considerable - UK guidance
recommends antidepressant treatment extends at least six
months after remission of symptoms and for a minimum
of two years for those at risk of relapse [7], and reviews
every 2–3 months are needed to assess the continued
need for pharmacological treatment of generalised anxiety
and panic disorders [8].
Treatment may be interrupted by pregnancy, when many
women discontinue pharmacotherapy [9] for reasons that
will likely centre around the perception of potential risk of
harm to the foetus. The absolute and relative risks of harm
are a subject of controversy, some studies have found a
small increased risk of some birth defects associated with
SSRI use in early pregnancy e.g. [10], although others have
not [11]. Expectant mothers may grossly over-estimate any
risks [12], which may mis-inform the decision to discon-
tinue. Both gradual and abrupt discontinuation from anti-
depressants and benzodiazepines in general populations
can result in a variety of temporary distressing withdrawal
symptoms, although absolute rates have proven difficult to
establish, and there are few studies in pregnancy [13–15].
Of greater clinical concern to the mother and her child is
for potential relapse following discontinuation, although
little research has been conducted and the two are not
conclusively linked [16, 17]. A general increased risk of
relapse is associated with greater initial episode severity,
and a higher number of previous episodes [16, 17]. There
is, however, growing evidence for the negative conse-
quences of untreated CMD during pregnancy for the
mother, her developing foetus and the child in later life
[18]. Even mild or subclinical disorder causes morbidity
and can result in harmful consequences for some offspring
of those affected [19]. In the UK, guidance issued to the
National Health Service (NHS) promotes access to
non-pharmacological treatments for CMD during preg-
nancy, stepping up with disorder severity to low dose
pharmacological treatment, preferably monotherapy, as
needed [20, 21]. There are few data to illustrate the
extent to which the treatment gap after reduction of
pharmacotherapy is filled by other therapies, including
psychological treatment.
Rates of common mental disorders (CMD) in the
community are higher for those who are socially and
economically disadvantaged [22]. People originating
from South Asia comprise 5.3 % of the population of
England and Wales and, in general, these minority eth-
nic groups are at higher risk for CMD because they are
disproportionally disadvantaged; they may also face
additional burden on their mental health due to racism
or discrimination [23–26]. Certain sub-groups of ethnic
minorities are at higher risk of mental disorder, for
example recently migrated South Asian women have
around double the burden of distress compared to sec-
ond or third generation migrants [27].
The Equality Act 2010 decrees that NHS treatment and
care should be equitable at point of access, including
treatment for common mental disorders. The small num-
ber of studies examining CMD treatment disparities for
ethnic minorities in the UK and US, however, indicate
inequitable prescribing and access to talking therapies
[25, 28, 29]. One study in London found variation in
the types of drugs prescribed (anxiolytics/hypnotics vs.
antidepressants) by ethnicity [30]. There are few pub-
lished data describing variation in treatment, or under
treatment, in the maternal period. This is important to
investigate because the higher fertility rate of some
minority ethnic women [31, 32] combined with greater
risk of mental disorder means that any treatment dis-
parity or variation would have disproportionately large
effects on minority ethnic communities.
The Born in Bradford (BiB) birth cohort study pro-
vides an ideal data source in which to examine potential
minority ethnic inequalities in CMD treatment during
pregnancy. Bradford is a city of around 500,000 inhabi-
tants in the North of England with high levels of socio-
economic deprivation and ethnic diversity. BiB was set
up to examine the impact of environmental, psycho-
logical and genetic factors on maternal and child health
[33, 34]. Over 12,000 women were recruited during their
pregnancy, BiB participants gave permission for their
demographic, health and socio-economic data provided
at recruitment to be linked with routinely collected
sources of data. Previously we have used linked BiB
research and primary care data to uncover ethnic dispar-
ities in the identification of CMD in primary care [35].
In this study we aimed to examine the quantity and
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types of treatments offered to women who were identi-
fied with CMD before, during and up to one year post-
natally, and assess if there was variation in disorders or
treatment by ethnic group.
Our research questions were:
1) To what extent is pharmacological treatment
curtailed and replaced by non-pharmacological treat-
ment during pregnancy?
2) Do disorder and treatment offered vary by maternal
ethnicity?
Methods
Population
Women were recruited for the BiB cohort study at the
Bradford Royal Infirmary (BRI) between 2007 and
2010, most while waiting for a universally offered glu-
cose tolerance test (GTT) at 26–28 weeks pregnancy
[33, 34]. Around 80 % of women attend for their GTT,
and >80 % of attendees consented to be recruited into
BiB. Most of the enrollees (83 %) filled out a question-
naire reporting socio-demographics, health status and
economic situation at recruitment. Enrolled women
consented to linkage of routine data and ethics ap-
proval for the data collection was granted by Bradford
Research Ethics Committee (Ref 07/H1302/112). The
enrolled cohort is broadly similar to the pregnant
population served by the BRI [34].
Study data
Data were collected from three sources and linked.
Questionnaire at recruitment
We classified self-reported ethnicity into two analytic
groups, White British and minority ethnic, based on
each woman’s response to questions about ethnic group
and cultural background in the recruitment question-
naire. Further decomposition of the minority ethnic
group was not practical due to small numbers available
for analysis. Self-reported age was obtained from the
questionnaire, and we noted which women enrolled sub-
sequent pregnancies into BiB.
Maternity database
For women giving birth at the BRI, gestational age at
birth and date of birth were obtained from the electronic
maternity database and used to calculate date of concep-
tion. We performed a simple imputation of gestation as
date of birth minus 280 days for the few women who
did not give birth at the BRI but whose baby’s date of
birth was obtained from summary care records or other
NHS sources. We used parity as indicated in the hospi-
tal’s maternal record; if this was missing we used the
mother’s self-reported parity from the recruitment
questionnaire. The first trimester was defined as the
conception date through the first 90 days.
Primary care records
Nearly all of Bradford’s primary care practices use Syst-
mOne clinical software (© TPP) in which clinical and
administrative terms are classified by Read codes, and
prescriptions captured using the British National Formu-
lary (BNF) dictionary. SystmOne electronic primary care
records were matched to BiB research records by a third
party data provider using the NHS number up to Febru-
ary 2013. Matching primary care records were identified
for 11,303 (90.8 %) BiB research records.
Mental health data We adapted previously published
methods to compile lists of Read codes [36] relevant to
the identification (signs, symptoms or diagnoses) and
non-pharmacological treatment (primary care treatment,
referrals to secondary and community care, or follow-
up) of CMD, and searched records for prescriptions of
drugs used to treat CMD, pharmacological treatment
(Additional file 1: Table S1). We used a sensitive set of
Read codes to indicate non-pharmacological treatment,
such as GP follow up for a mental health problem, in
order to capture events for women where primary treat-
ment or referral may have been recorded just prior to
our study period, but treatment took place during the
study period. We separated identification Read codes into
those that indicated depression, or depressive symptoms,
and those that indicated anxiety, or anxiety symptoms.
We did not have access to free-text notes and referral let-
ters due to third party data protection concerns.
Data on further pregnancies We identified women
with further pregnancies that they did not enrol into BiB
from primary care records using a Read code search
with pregnancy, abortion and foetal death terms, adapt-
ing previously published codes [37]. The sensitivity of
using the routine data to identify the (known) index
pregnancy was 96.0 % (95 % CI: 95.6 to 96.4).
Exclusions
We used NHS tracing files, which indicate current area of
residence each year, to exclude women who moved from
Bradford between enrolment and the end of the first post-
natal year. This minimised potential unknown missing
data bias caused by some women having incomplete pri-
mary care records because they moved to a practice not
using SystmOne. We were not able to obtain these data
prior to enrolment. We also excluded women with no
linked primary care records, with Read codes or prescrip-
tions indicating the possibility of severe mental illness
(psychoses, bipolar, schizophrenia), with missing date of
birth for the index baby, with a pregnancy in the six-
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month pre-conception period, who did not fill in the
questionnaire at recruitment, who did not provide their
ethnicity on the questionnaire, and with missing parity.
We excluded occurrences of drugs that had current
indications in the BNF for being used to treat medical
conditions in addition to CMDs (in this sample this
was chlordiazepoxide, doxepin and duloxetine).
Included sample
We selected one index pregnancy per mother. If a mother
had enrolled multiple pregnancies during the BiB study
enrolment period (12,450 women enrolled 13,773 preg-
nancies), we used the first enrolled pregnancy where she
had completed a recruitment questionnaire providing her
ethnicity. We used data from all women who, at any time
in the period between six months prior to conception and
12 months after the index birth, had markers in the med-
ical record of identification, and/or non-pharmacological
treatment, and/or pharmacological treatment of CMD.
Analysis periods
To investigate replacement of pharmacological with non-
pharmacological treatment we defined a period encompass-
ing the pregnancy. Women were included in this analysis if
they had received at least one prescription during preg-
nancy. We defined two further separate time periods to
examine whether treatment varied by ethnicity. The first
period spanned from six-months prior to conception up to
the birth, the ‘pre-delivery’ period, and the second was
delivery to 12 months post-delivery; the ‘first postnatal
year’. Women included in each analysis period were those
who were identified or treated within that period.
Derived dependent variables
Derived variables are summarised in Table 1.
Identification of CMD Women included for each ana-
lysis period were those with identification or treatment
indicators, however many women only had indicators of
treatment (e.g. a prescription, or a referral to a community
mental health team) with no corresponding indication of
the nature of the problem. Incomplete ascertainment of
disorder or problem is common in mental disorder studies
that analyse medical records [38, 39]. In order to examine
treatments in relation to need, we first classified a binary
variable of women being identified with CMD in that
period.
Identified indication For those women who were identi-
fied, we constructed a binary variable of their indication,
classifying women with an anxiety-related Read code in
that period versus women who had depression-related
only Read codes. In the interest of parsimony in our small
sample, women with co-morbid anxiety and depression
disorders, and women who had both anxiety and
depression-related Read codes in the same period were
classified as having anxiety. We further constructed a
three-category indication variable (anxiety, depression and
both) in order to examine counts by pharmacological
treatment.
Treatment for CMD In order to examine differences in
the types of treatments recorded we categorised identified
women as having pharmacological treatment only, non-
pharmacological treatment only, both types of treatment,
or no treatment in that period in a four-category variable.
Pharmacological treatment for CMD We characterised
prescribed drugs as those that were primarily antidepres-
sant and those that were primarily anxiolytic/hypnotic
(Table 2) and derived a variable that classified women as
being prescribed drugs that were primarily antidepressant,
primarily anxiolytic or being prescribed both types of drug
in any one period.
Covariates
Covariates used in the analyses included maternal age
(continuous and quadratic), parity (0,1,2,3,4+), and a fur-
ther pregnancy in the first postnatal year (binary yes / no).
We constructed several binary indication and treatment
covariates. We classified a depression indication covariate
as the presence or absence of depression indicators in
the concurrent period, and, for postnatal analyses, these
Table 1 Summary of dependent variables
Variable Categories
Identification (binary) Presence of identification Read codes
Absence of identification Read codes
Identified indication
(binary)
Presence of anxiety Read codes
Presence of depression Read codes only
Identified indication
(three-category)
Presence of depression Read codes only
Presence of anxiety Read codes only
Presence of comorbid anxiety and
depression Read codes, or both anxiety
and depression Read codes
Treatment (four-category) Pharmacological treatment only
Non-pharmacological treatment only
Both types of treatment
No treatment
Pharmacological treatment
(three-category
Treated with drugs that are primarily
antidepressant
Treated with drugs that are primarily
anxiolytic
Treated with both types of drugs
Dependent variables were separately derived for each analysis period (pre-
birth, postnatal year), see text for further description
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indicators during the pre-birth period. We similarly
constructed an anxiety indication covariate for the con-
current and pre-birth periods. A pharmacological treat-
ment covariate was the presence or absence of
pharmacological treatment in the pre-birth period
(used in postnatal analyses); and we similarly defined a
non-pharmacological treatment covariate.
Analysis
Replacement of pharmacotherapy with other treatments
during pregnancy
We assessed the replacement of pharmacological treat-
ment with non-pharmacological treatment during the
pregnancy using the denominator of women who had at
least one prescription issued during the pregnancy. In
this group, we counted the number of women who did
not have a prescription issued after the first trimester
and had an indication of non-pharmacological treatment
in the medical record at any point during the pregnancy.
We noted the number of prescriptions by drug group
and class. Potential ethnic differences in treatment re-
placement were not investigated due to small numbers.
Variation in treatment by ethnic group
Identification of CMD Potential variation in identifica-
tion by ethnic group were investigated using Poisson
regression, reporting the adjusted relative risk (aRR) for
minority ethnic women compared to White British
women in each period. We adjusted the pre-delivery
analyses for maternal age and parity, and the postnatal
analysis for maternal age, parity, further pregnancy,
pre-birth depression and anxiety indication covariates
and pharmacological and non-pharmacological treat-
ment covariates.
Identified indication For this analysis, we included only
women with identification Read codes. Potential variation
in identification by ethnic group were investigated using
Poisson regression on the binary identified indication vari-
able, reporting the aRR for minority ethnic women com-
pared to White British women in each period. We
adjusted the pre-delivery analyses for maternal age and
parity, and the postnatal analysis for these plus further
pregnancy, pre-birth depression and anxiety indication co-
variates and pharmacological and non-pharmacological
treatment covariates.
Treatment type Again including only women with iden-
tification Read codes we applied multinomial logistic
regression to the treatment type variable, holding
‘pharmacological treatment only’ as the reference cat-
egory and reporting the aRR for minority ethnic women
compared to White British women in each period. We
adjusted the pre-delivery analyses for maternal age, par-
ity and concurrent depression and anxiety indication co-
variates, and the postnatal analysis for these plus further
pregnancy, and pre-birth depression and anxiety indica-
tion covariates. Due to small numbers we were not able
to further stratify the analysis by the type of indication
(depression / anxiety). Instead we graphed unadjusted
proportions of women in each ethnic group who
received prescriptions of different groups of drugs by the
three-category indication variable.
Post-hoc, we noted a number of prescriptions for pro-
panolol (sometimes prescribed as an anxiolytic), which
had, prior to the study, been (until 2007) labelled as a
first line anti-hypertensive. To assess whether this
affected our results we repeated all regression analyses
adjusting for hypertension in pregnancy (the presence or
absence of hypertension was ascertained from the elec-
tronic maternity system for 88.2 % of women).
We present 95 % confidence intervals (CI) around risk
estimates and used Stata release 13 (StataCorp. 2013.
Table 2 Drug classification
Drug group Drug class Drug name
Primarily antidepressant SSRI fluoxetine
citalopram
escitalopram
sertraline
paroxetine
cipramil
cipralex
fluvoxamine
SNRI venlafaxine
TCA dosulepin
clomipramine
imipramine
lofepramine
SARI trazodone
NaSSA mirtazapine
Primarily anxiolytic BETA-B propranolol
BENZ diazepam
temazepam
lorazepam
loprazolam
oxazepam
nitrazepam
non-BENZ HYP zopiclone
SED-HYP zolpidem
Lists all drugs found in medical records spanning the whole study period
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Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP) to conduct all analyses.
Results
Included sample
We included 2,234 women with CMD (as defined in the
Methods) during the study period (Fig. 1). Our sample
consisted of 1,251 women of White British ethnicity and
983 minority ethnic women (Table 3). We have previ-
ously reported that, for similar levels of self-reported
psychological distress, minority ethnic women in BiB
were less likely to be identified in primary care as having
CMD compared to White British women, which we
interpret as a primary care identification disparity [35].
Therefore, White British women are over-represented in
this analysis (56.0 %) compared to the proportion
enrolled in BiB (39.5 %) [34]. Mean age at recruitment
for our analysed sample was 26.8 years (standard devi-
ation 5.9). Seventy-six per cent of minority ethnic
women and 54 % of White British women lived in areas
ranked as the fifth most deprived nationally on the Index
of Multiple Deprivation 2010.
The number of women included in the analyses (i.e.
had any Read codes relating to CMD, or prescriptions
for treating CMD) in the pre-delivery period was 750
(N = 439 White British, 58.5 %; N = 311 minority eth-
nic, 41.5 %) and 1,039 in the postnatal year (N = 645
White British, 62.1 %; N = 394 minority ethnic, 37.9 %).
Fifteen per cent of women (N = 335) were included in
analyses at both time periods (N = 233 White British
69.6 %; N = 102 minority ethnic, 30.5 %).
Replacement of pharmacological with non-pharmacological
treatment during pregnancy
During pregnancy, 298 women had one or more pre-
scriptions issued and 144 women had at least one Read
code indicating non-pharmacological treatment. Of the
809 prescriptions issued, 69.1 % were for an SSRI
(Table 4). Eighty-six per cent of women received an anti-
depressant and 22.6 % an anxiolytic (some received
both). Nearly 60 % (N = 174) of the 298 women on
pharmacological treatment did not have a prescription
dated after the end of the first trimester, when most
pregnancy-related pharmacological discontinuation
would have taken place. Women who discontinued were
just as likely to have been prescribed an antidepressant
(86.2 %) and/or anxiolytic (20.7 %) as those who contin-
ued. Only 26 of the 174 women with ceased prescrip-
tions (14.9 %; White British 15.1 %, minority ethnic
14.7 %) had a Read code in their medical record indicat-
ing provision of a non-pharmacological treatment during
the pregnancy.
Variation by ethnic group
Estimates for regression analyses by ethnic group are
presented in Table 5.
Identification
Fifty-six percent of women had at least one identification
Read code in the pre-delivery period and 65 % in the
first postnatal year. Similar proportions of women in
each ethnic group had identification Read codes.
Recruited N=12,450 women
Included
N=10,859
N=1,591
Reasons (women could be excluded for >1 reason)
No birthdate recorded for index baby N=96
Primary Care record not matched N=1,147 
LSOA could not be established N=3
Incorrect join N=1
and
Moved from Bradford 
o Yes (N=505)
o Could not establish whether moved within 
postnatal study period (N=155)
Excluded
N=2,234
N=8,571
Reasons (women could be excluded for >1 reason)
No markers of  CMD identification or treatment during study 
period N=7,691
Possible severe  mental illness (N=189)
Indication of pregnancy in 6-month index pregnancy pre-
conception period (N=277)
Ethnicity not provided (N=435)
Parity could not be ascertained (N=54)
Fig. 1 Study flowchart
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Identified indication
Minority ethnic women were 69 % more likely to have
indications of anxiety rather than depression in the pre-
delivery period compared to White British women (simi-
larly 55 % more likely in the first postnatal year).
Treatment type for those identified
In the pre-birth period, holding pharmacological treat-
ment only as the reference category, compared to
White British women, minority ethnic women were
nearly twice as likely to have no treatments recorded.
A similar result was observed when analysing data
from the first postnatal year, where additionally, mi-
nority ethnic women were less than half as likely to
have both pharmacological and non-pharmacological
treatment. Very few women in either period had non-
pharmacological treatment only. All results were
robust to adjusting for hypertension during pregnancy
(data not shown).
Drug group by indication
Visual inspection of unadjusted counts of drug group/s
prescribed by indication revealed little variation by
ethnic group (Fig. 2).
Table 3 Participant characteristics
White British Minority ethnic All
N 1,251 983 2,234
Age at recruitment, mean (SD) 25.9 (6.0) 27.9 (5.6) 26.8 (5.9)
Parity at recruitment, n (%) First child 614 (49.1) 373 (38.0) 987 (44.2)
1 369 (29.5) 230 (23.4) 599 (26.8)
2–3 225 (18.0) 295 (30.0) 520 (23.3)
4+ 43 (3.4) 85 (8.7) 128 (5.7)
Further pregnancy in 12 months postnatal period, n (%) No 1,149 (91.9) 869 (88.4) 2,018 (90.3)
Yes 102 (8.2) 114 (11.6) 216 (9.7)
Ethnic group, n (%) White British 1,251 (100) - 1,251 (56.0)
Pakistani - 749 (76.2) 749 (33.5)
Mixed - 64 (6.5) 64 (2.9)
Indian - 44 (4.5) 44 (2.0)
White non-British - 32 (3.3) 32 (1.4)
Black - 27 (2.8) 27 (1.2)
Bangladeshi - 26 (2.6) 26 (1.2)
Other - 41 (4.2) 41 (1.8)
Country of birth and age at migration, n (%) Born in UK 1,233 (98.6) 491 (50.0) 1,724 (77.2)
Immigrated before age 16 13 (1.0) 132 (13.4) 145 (6.5)
Immigrated 16 or older 2 (0.2) 347 (35.3) 349 (15.6)
Missing 3 (0.2) 13 (1.3) 16 (0.7)
Language used during recruitment, n (%) English 1,250 (99.9) 751 (76.3) 2001 (89.6)
Other language 0 224 (22.8) 224 (10.0)
Missing 1 (0.1) 8 (0.8) 9 (0.4)
Marital/cohabitation status at recruitment, n (%) Married & living together 328 (26.2) 791 (80.5) 1,119 (50.1)
Cohabiting 503 (40.2) 41 (4.2) 544 (24.4)
Not living with a partner 419 (33.5) 151 (15.4) 570 (25.5)
Missing 1 (0.1) 0 1 (0.4)
Index of Multiple Deprivation (2010) national rank at recruitment, n (%) Most deprived 673 (53.8) 751 (76.4) 1,424 (63.7)
2 253 (20.2) 146 (14.9) 399 (17.9)
3 220 (17.6) 74 (7.5) 294 (13.2)
4 75 (6.0) 4 (0.4) 79 (3.5)
Least deprived 30 (2.4) 8 (0.8) 38 (1.7)
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Discussion
Summary of findings
We analysed routinely collected primary care data from
2,234 maternal women with markers of common mental
disorders living in an ethnically diverse and economically
deprived city. The majority of women were discontinued
from pharmacologic treatment prior to and during preg-
nancy but this did not appear to be balanced by an in-
crease in access to non-drug treatment such as
psychological therapies. Minority ethnic women were
more likely than White British women to have a marker
of diagnosis, symptoms or signs of anxiety rather than
depression in their medical record. Adjusted for indica-
tion, minority ethnic women appeared to have less ac-
cess to treatment both pre- and post-birth, and were less
likely to be recorded as being treated with both pharma-
cology and non-pharmacological modalities in the post-
natal year than White British women.
a. Prebirth
White British N=170, Minority ethnic N=90
b. Post-natal year
White British N=359, Minority ethnic N=152
Fig. 2 Drug group by indication by ethnic group (a) pre-birth (b) post-natal year
Table 4 Number of prescriptions issued during pregnancy by
drug type and class
Drug group N % Drug class N %
Primarily antidepressant 689 85.2 SSRI 559 69.1
SNRI 56 6.9
TCA 35 4.3
SARI 26 3.2
NaSSA 13 1.6
Primarily anxiolytic 120 14.8 BETA-B 31 3.8
BENZ 39 4.8
non = BENZ 50 6.2
809 100 809 100
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Strengths and limitations
This study included a large number of minority ethnic
women with accurate data on gestation dates and further
pregnancies. We used a broad definition of CMD to
minimise recording variation in the medical record. Re-
search data were linked to the primary care record using
unique identifiers, minimising differences in quality of
non-unique personal identifiers between ethnic groups.
The tight geographic focus minimises potential bias due
to regional variation in coding or prescribing practices
which could be confounded with ethnic density in differ-
ent regions. This study demonstrates the power of data
linkage to address important health services research
questions and identify areas for quality improvement.
Our study has several limitations. There was some
overlap in women included in analyses for both time pe-
riods which may have affected our estimates. Due to
small numbers we were not able to sensibly analyse the
data by more precisely defined ethnic groups, which will
have led to potentially substantial heterogeneity within
our categorised groups. We had no access to medical re-
cords prior to six-months pre-conception which will
have led to an under-estimate of treatments if referrals
or prescriptions were made just before this date, or iden-
tification was noted prior to this date. Additionally, we
did not have access to the contents of referral letters or
free-text notes which may have led to under-estimates,
or the misrepresentation of inequalities, if these data
were systematically different by ethnic group. The recog-
nition and management of CMDs by midwives or health
visitors may not have been recorded in the electronic
record, but because GPs should be notified of suspected
CMD [20, 21], we do not think this impacted materially
on our results.
For classifying women as ‘identified’ we did not rely
on Read codes indicating diagnoses because they have
only 6–26 % sensitivity for disorder [38, 39], recording
of diagnoses versus symptoms appears to change over
time [38, 40], and we were unsure whether either of
these factors also varied by practice. We had no indica-
tion of illness severity, and combining symptoms and
signs with diagnoses may have hampered our analysis of
whether and with what ‘identified’ women were ‘treated’
if this varied by ethnic group. Our Read code list, while
extensive, may not be exhaustive. By including Read
codes for community referrals and monitoring appoint-
ments we operationalised a rather liberal definition of
non-pharmacological treatment which may include
women who were not in receipt of an effective treat-
ment. Our definition of ‘treatment’ will overestimate the
number of women actually undergoing treatment
because we did not know which women started, com-
pleted, or dropped out of treatment. This means actual
treatment rates are lower than reported here. In line
with other estimates of general and maternal primary
care attendees [39, 41, 42], treatment rates in this cohort
Table 5 Relative risk of treatment and disorder type by ethnic group
Pre-delivery First postnatal year
White British
N = 439
Minority
ethnic N = 311
Minority ethnic vs.
White British
White British
N = 645
Minority
ethnic N = 394
Minority ethnic vs. White
British
n % n % aRR (95 % CI) n % n % aRR1 (95 % CI)
Identification Read codes
At least one (ref. none) 247 56.3 175 56.3 1.03 (0.85, 1.26) 442 68.5 236 59.9 0.88 (0.75, 1.03)
Identified indication N = 247 N = 175 N =
442
N = 236
Anxietya (ref. depression only) 67 27.1 83 47.4 1.69 (1.22, 2.35) 66 14.9 63 26.7 1.55 (1.08, 2.23)
Treatment type for those
identified
aRR2 (95 % CI) aRR3 (95 % CI)
Pharmacological only 98 39.7 58 33.1 ref. 229 51.8 121 51.3 ref.
Non-pharmacological only 22 8.9 16 9.1 1.39 (0.64, 3.02) 14 3.2 14 5.9 2.02 (0.90, 4.54)
Both types of treatment 72 29.2 32 18.3 0.85 (0.49, 1.47) 130 29.4 31 13.1 0.42 (0.26, 0.68)
None 55 22.3 69 39.4 1.96 (1.14, 3.37) 69 15.6 70 29.7 1.74 (1.14, 2.69)
a includes women with comorbid anxiety and depression
aRR Poission regression reporting relative risk adjusted for maternal age and parity
aRR1 Poission regression reporting relative risk adjusted for maternal age, parity, anxiety/depression Read codes and treatment type (pharmacological/
non-pharmacological) in the pre-delivery period, further pregnancy in the postnatal year
aRR2 Multinomial logistic regression reporting relative risk adjusted for maternal age, parity, concurrent anxiety/depression Read codes, further pregnancy in the
postnatal year
aRR3 Multinomial logistic regression reporting relative risk adjusted for maternal age, parity, concurrent anxiety/depression Read codes, anxiety/depression Read codes
and treatment type (pharmacological/non-pharmacological) in the pre-delivery period, further pregnancy in the postnatal year
CI confidence interval
bolded estimates are statistically significant
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under-represent the number in potential need with psy-
chological distress undetected in primary care for an es-
timated 31–47 % of women [35]. Because minority
ethnic women are more than twice as likely to have an
unrecognised disorder and therefore no NHS treatment
[35], our results are conservative and under-represent
absolute disparity in service use and treatment need.
Our estimates are of event coding in the medical record
and not treatment uptake or success, neither are they
adjusted for need, which may vary considerably between
and within ethnic groups. The lack of a reliable indicator
in primary care of disorder severity or amelioration
meant we could not differentiate between women who
were discontinued from pharmacotherapy because they
no longer needed treatment, and those with active dis-
order requiring further support. This may have affected
our findings if discontinuation by indication varied
between ethnic groups.
Other factors such as education or ability in English
may influence treatment sought or received, such as ac-
cess to psychological therapies, but it was beyond the
scope of our descriptive study with small numbers of
treated women to further stratify our analyses. As with
all analyses of routine general practice in the UK there
are no linked data to indicate which prescriptions were
filled, or which courses were completed, and we did not
have diagnostic data available which would have enabled
more accurate estimation of treatment inequalities. We
did not have access to information about non-NHS
treatments, such as private counselling, which may vary
between ethnic and socio-economic group. Finally, the
cohort is based in one city and results may not be gener-
alisable to other areas, or nationally.
Treatment during pregnancy
Our study agrees with other data from the UK, Nordic
countries and the Netherlands showing that most
women taking antidepressants prior to or at the start of
pregnancy discontinue them before delivery [9, 43–45].
Our results add to this literature by demonstrating that,
for most women, withdrawal from pharmacological
treatment does not seem to be replaced with alternative
active treatments. The implication is that a proportion
of women with active anxiety or depression symptoms are
simply waiting out their pregnancy without treatment. UK
guidance covering the study period recommended that
after withdrawal of pharmacological treatment of mild
depression before or during pregnancy, doctors should
monitor symptoms or consider referral for brief psycho-
logical treatment [20]. New guidance brought in after the
end of our study period recommend facilitated self-help in
these cases [21]. For those experiencing moderate or
severe depressive episodes, and those with anxiety, recom-
mendations were to switch drugs to those with a better
safety profile, or switch to a psychological treatment [20].
These recommendations are unchanged in the new guid-
ance, with increased emphasis on the management of anx-
iety disorders in pregnancy, for which non-pharmacological
treatment is the preferred option [21].
Assuming all those in our sample who were treated
pharmacologically had CMD, that depression accounted
for 50 % of diagnoses, and that 70 % of depression cases
were mild [46], then 65 % of women had either anxiety,
or a moderate to severe depressive episode that guide-
lines suggest should have remained on treatment. Our
results indicate that only 15 % of women who discontin-
ued were offered non-pharmacological treatment by the
end of gestation, but women in active treatment at any
one time will have been lower, as we could not adjust
for cessation of time-limited psychological therapy, time
lag between referral and uptake, or take up rate. It seems
unlikely that 85 % of women discontinuing pharmaco-
therapy during the first trimester had ameliorated symp-
toms that did not require any further treatment. Rates of
replacement therapy do not appear to approach the
potential need and raise serious questions about in-
creased risk of morbidity to the mother, the foetus and
the family. During the study period the Improved Access
to Psychological Therapy (IAPT) programme was piloted
and then rolled out in England by the Department of
Health with an aim of equitably treating people with
CMD using evidence-based talking therapies (largely
cognitive behavioural therapy but also including interper-
sonal and brief dynamic interpersonal psychotherapy, and
counselling and couples therapy for depression) [47, 48].
The IAPT programme aims to treat 15 % of CMD preva-
lent in the community, or, allowing for patient choice,
72 % of those identified in primary care [48]. In time this
programme has the potential to close this apparent treat-
ment gap, however, demand currently outstrips provision,
leading to long waiting times [48] that might outlast the
pregnancy for some. Initial analyses indicate potential dis-
parity in uptake and outcomes [49] and acceptability and
local availability of non-pharmacological treatment as
potential sources of health inequality requires further in-
vestigation, particularly in respect to cultural adaptation of
interventions for South Asian women and non-English
speakers [50]. Further research into treatment decision-
making in primary care is needed, including training and
education gaps [51].
Treatment inequalities
National studies utilising prescription data (without
accounting for specific disorders) have found associa-
tions between increased prescribing of anxiolytics/hyp-
notics and antidepressants in practices based in areas
of high deprivation, and some evidence for decreased
prescribing in areas with greater proportions of Asian,
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Asian British or minority ethnic patients, and in single-
handed practices [52–55]. As minority ethnic women are
more likely to live in areas of higher deprivation in the
Bradford district, they may encounter dual inequalities
linked to both cultural and geographic factors.
Our finding of potential treatment variation for minority
ethnic (mostly Pakistani) women adds information about
the maternal period to, and broadly concurs with, other,
non-maternal, studies on minority ethnic inequalities. Our
denominator only included primary care attendees with
markers in their medical record that are indicative of
CMD. When inequalities related to primary care detec-
tion rates are factored in, the risks of under-treatment
for ethnic minorities in the community will be higher
[28, 35, 56]. While our analysis did not uncover gross
prescribing differences, small numbers and a lack of
precision may have hampered our analysis. In an English
nationally representative study Cooper and colleagues
found that, after controlling for symptom severity, White
people were twice as likely to be prescribed antidepres-
sants for CMD compared to Black people [28]. Small
numbers hampered analysis in South Asian ethnic groups
and anxiolytics were not studied. Gater and colleagues in
a study based in the city of Manchester found that White
European women who were depressed, according to a
diagnostic interview outside of the primary care setting,
were twice as likely to have medical records that indicated
antidepressant prescriptions (50 % vs 23 %) and four times
more likely (25 % vs 6 %) to have been given psychological
treatment than depressed Pakistani women [25]. Eco-
logical data from East London found that practices with
high numbers of Asian people on their lists prescribed
slightly more antidepressants compared to anxiolytics/
hypnotics [30].
Our finding that minority ethnic women were more
likely to be identified with anxiety/report anxiety symp-
toms than depression/depressive symptoms compared with
White British women is new, but the implications difficult
to interpret without more accurate diagnosis information.
It could indicate a true difference in specific disorder
prevalence by ethnicity in this sample. If so, because treat-
ments for anxiety are primarily psychological, we would
expect more minority ethnic women to be accessing
non-pharmacological treatments, which they did not.
This may indicate the under-provision of culturally
adapted psychologically-based treatments. Although
small numbers prevented us exploring the relationship
between disorder type and specific treatments further,
our results may indicate increased prescription of anxi-
olytics for need, which is a concern in view of the long
recognised risks of tolerance and dependence. Alterna-
tively, our finding may point to over-characterisation of
minority ethnic women with anxiety rather than
depression, along with potentially increased levels of
inappropriate prescription of anxiolytics for depressive
symptoms. There is little other evidence on specific dis-
order prevalence for different ethnic groups, but one
study of a nationally representative sample did not
detect statistically significant variation [24]. Long
standing questions over the validity of cross-cultural
measurements and differential accuracy of diagnoses
still hinder our understanding in this area [57, 58]. Fur-
ther research using larger samples, longitudinal data
and mixed methods are needed to replicate these and
other findings and unpick whether there are differences
in need (i.e. severity and type of illness varies by ethnic
group), variation in Read coding by patient (or pro-
vider) ethnic group, systematic differences in preference
whereby certain treatments are less attractive to minor-
ity ethnic women, or whether there is variation in the
type of treatments offered to women of different ethnic
groups by GPs.
The dearth of research into maternal ethnic mental
health disparities translates to a lack of specific advice
to primary care healthcare practitioners, who identify
and treat the majority of CMD cases, on how to
ensure that identification and treatment choices are
equitable. Even where advice is clear, the gap between
best and actual practice may be large [59]. Primary
and community care staff need support, including
better data, to enable them understand the impact of
mental health inequalities on their patients and how
to address them [60].
Conclusions
We found evidence of mental health variation and po-
tential disparities for maternal minority ethnic women
that warrant further investigation to close health in-
equality gaps. While most women are discontinued from
pharmacological treatment during pregnancy according
to treatment guidelines, the seeming lack of provision of
alternative active treatments is concerning and may have
significant future negative effects for families.
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